We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 21

Europe sees strong growth in biotech patent filings
  • Shook Hardy & Bacon LLP
  • European Union
  • April 21 2011

According to a news source, biotechnology patent applications filed with the European Patent Organization (EPO) grew more than 42 percent in 2010 from the previous year


News bytes
  • Shook Hardy & Bacon LLP
  • European Union, USA
  • December 16 2010

The European Medicines Agency (EMA) adopts two draft guidelines as part of the regulatory approval process for certain biosimilar medicinal products


European nations sign MOU to manage life-science information
  • Shook Hardy & Bacon LLP
  • European Union
  • September 22 2011

Denmark, Finland, the Netherlands, Sweden, and the United Kingdom have reportedly signed a memorandum of understanding (MOU) with the European Molecular Biology Laboratory to create an infrastructure that would both manage and safeguard life-science data generated by publicly funded research


European Commission study recommends changes to medical device and drug laws
  • Shook Hardy & Bacon LLP
  • European Union
  • May 17 2012

The European Commission has issued a report that analyzes the European Union’s (EU’s) REACH regulation, which addresses the registration, evaluation, authorization and restriction of chemical substances, and identifies overlap with other EU laws


EU Court of Justice interprets law extending patent protection for medicinal products
  • Shook Hardy & Bacon LLP
  • European Union
  • December 15 2011

The Court of Justice of the European Union (ECJ) has issued two rulings interpreting EU law at the request of British courts addressing whether drug makers can obtain a supplementary protection certificate (SPC), which extends patent protection, for products with active ingredients additional to those specified in the original patent


European Medicines Agency seeks feedback on biosimilars guideline
  • Shook Hardy & Bacon LLP
  • European Union
  • December 15 2011

The European Medicines Agency has issued for public comment a “Concept paper on the revision of the guideline on similar biological medicinal product.”


EU regulators charge pharma companies with antitrust violations in pay-for-delay deals
  • Shook Hardy & Bacon LLP
  • European Union
  • August 2 2012

The European Commission (EC) has reportedly charged nine pharmaceutical companies with breaches of European Union (EU) antitrust rules for entering pay-for-delay deals with generic competitors


European Medicines Agency considers changes to biosimilar guidelines
  • Shook Hardy & Bacon LLP
  • European Union
  • October 20 2011

The European Medicines Agency (EMA) has published a concept paper outlining a number of clinical and non-clinical issues that need revision in its current “Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance"


Wellcome Trust creates £200-million fund for UK, EU biotech startups
  • Shook Hardy & Bacon LLP
  • European Union, United Kingdom
  • March 29 2012

The U.K.-based Wellcome Trust has announced the creation of a £200-million fund to make long-term investments in British and European biotechnology startups


Report suggests Europe could become marine biotech leader by 2020
  • Shook Hardy & Bacon LLP
  • European Union
  • January 13 2011

The Marine Board of the European Science Foundation has released a report that suggests Europe could become a global leader in marine biotechnology by 2020, particularly by cultivating microalgae for fuel